|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases显示文摘AIM: To investigate the effect of vitamin D(VD) concentrations and VD supplementation on health related quality of life in inflammatory bowel disease(IBD) patients. METHODS: A cohort of 220 IBD patients including 141 Crohn's disease(CD) and 79 ulcerative colitis(UC) patients was followed-up at a tertiary IBD center. A subgroup of the cohort(n = 26) took VD supplements for > 3 mo. Health related quality of life was assessed using the short IBD questionnaire(s IBDQ). VD serum concentration and s IBDQ score were assessed between August and October 2012(summer/autumn period) and between February and April 2013(winter/spring period). The mean VD serum concentration and its correlation with disease activity of CD were determined for each season separately. In a subgroup of patients, the effects of VD supplementation on winter VD serum concentration, change in VD serum concentration from summer to winter, and winter s IBDQ score were analyzed.RESULTS: During the summer/autumn and the winter/spring period, 28% and 42% of IBD patients were VD-deficient(< 20 ng/m L), respectively. In the winter/spring period, there was a significant correlation between s IBDQ score and VD serum concentration in UC patients(r = 0.35, P = 0.02), with a trend towards significance in CD patients(r = 0.17, P = 0.06). In the winter/spring period, VD-insufficient patients(< 30 ng/m L) had a significantly lower mean s IBDQ score than VD-sufficient patients; this was true of both UC(48.3 ± 2.3 vs 56.7 ± 3.4, P = 0.04) and CD(55.7 ± 1.25 vs 60.8 ± 2.14, P = 0.04) patients. In all analyzed scenarios(UC/CD, the summer/autumn period and the winter/spring period), health related quality of life was the highest in patients with VD serum concentrations of 50-59 ng/m L. Supplementation with a median of 800 IU/d VD day did not influence VD serum concentration or the s IBDQ score.CONCLUSION: VD serum concentration correlated with health related quality of life in UC and CD patients during the winter/spring period. | Tibor Hlavaty Anna Krajcovicova Tomas Koller Jozef Toth Monika Nevidanska Martin Huorka Juraj Payer | 2014 | World Journal of Gastroenterology2014，20，42： | 11 |
| 2 | Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study显示文摘AIM To analyze 1-year liver injury burden in inflammatory bowel disease(IBD) patients. METHODS During a 6-mo inclusion period, consecutive IBD cases having a control visit at IBD center were included. Basic demographics, IBD phenotype and IBD treatment were recorded on entry. Aminotransferase(AT) activities of ALT, AST, ALP and gamma-glutamyl transpeptidase(GGT) were measured at baseline, 3 mo prior to study entry and prospectively every 3 mo for 1 year. Liver injury patterns were predefined as: Grade 1 in ALT 1-3 × upper limit of normal(ULN), grade 2 in ALT > 3 × ULN, hepatocellular injury in ALT > 2 × ULN, cholestatic injury in simultaneous GGT and ALP elevation > ULN.Persisting injury was reported when AT elevations were found on > 1 measurement. Risk factors for the patterns of liver injury were identified among demographic parameters, disease phenotype and IBD treatment in univariate and multivariate analysis. Finally, implications for the change in IBD management were evaluated in cases with persisting hepatocellular or cholestatic injury.RESULTS Two hundred and fifty-one patients were included having 917 ALT and 895 ALP and GGT measurements. Over one year, grade 1 injury was found in 66(26.3%), grade 2 in 5(2%) and hepatocellular injury in 16 patients(6.4%). Persisting hepatocellular injury was found in 4 cases. Cholestasis appeared in 11 cases(4.4%) and persisted throughout the entire study period in 1 case. In multivariate analysis, hepatocellular injury was associated with BMI(OR = 1.13, 1.02-1.26), liver steatosis(OR = 10.61, 2.22-50.7), IBD duration(1.07, 1.00-1.15) and solo infliximab(OR = 4.57, 1.33-15.7). Cholestatic liver injury was associated with prior intestinal resection(OR = 32.7, 3.18-335), higher CRP(OR = 1.04, 1.00-1.08) and solo azathioprine(OR = 10.27, 1.46-72.3). In one case with transient hepatocellular injury azathioprine dose was decreased. In 4 cases with persisting hepatocellular injury, fatty liver or alcohol were most likely causes and IBD treatment was pursued without change. In the case with persisting cholestatic injury, no signs of portal hypertension were identified and treatment with infliximab continued.CONCLUSION Liver injury was frequent, mostly transient and rarely changed management. Infliximab or azathioprine were confirmed as its risk factors indicating the need for regular AT monitoring. | tomas koller martina galambosova simona filakovska michaela kubincova tibor hlavaty jozef toth anna krajcovicova juraj payer | 2017 | World Journal of Gastroenterology2017，23，22： | 5 |
| 3 | Biological therapy in inflammatory bowel diseases:Access in Central and Eastern Europe显示文摘Biological drugs opened up new horizons in the management of inflammatory bowel diseases(IBD).This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European(CEE)countries,namely Bulgaria,the Czech Republic,Estonia,Hungary,Latvia,Lithuania,Poland,Romania and Slovakia.Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed.Moreover,we provide an estimation on prevalence of IBD as well as biological treatment rates.In all countries with the exception of Romania,lower biological treatment rates were observed in ulcerative colitis(UC)compared to Crohn’s disease despite the higher prevalence of UC.Great heterogeneity(up to 96-fold)was found in access to biologicals across the CEE countries.Poland,Bulgaria,Romania and the Baltic States are lagging behind Hungary,Slovakia and the Czech Republic in their access to biologicals.Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria,Latvia,Lithuania,and Poland,but association with other possible determinants(differences in prevalence and incidence,price of biologicals,total expenditure on health,geographical access,and cost-effectiveness results)was not proven.We assume,nevertheless,that healthdeterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD.In conclusion,access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors,drug prices or total health expenditure.Changes in reimbursement policy could contribute to better access to biologicals in some countries. | Fanni Rencz Márta Péntek Martin Bortlik Edyta Zagorowicz Tibor Hlavaty Andrzej Sliwczyński Mihai M Diculescu Limas Kupcinskas Krisztina B Gecse László Gulácsi Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，6： | 4 |
| 4 | The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women 显示文摘 | Kunesova M Braunerov R Hlavaty P | 2006 | Physiol Res2006，55，1： | 1 |
| 5 | Suicide genes for cancer therapy显示文摘 | Portsmouth D Hlavaty J Rennet M | 2007 | Mol Aspects Med2007，28，1： | 1 |
| 6 | Smoking,breastfeeding,physical inactivity,contact with animals,and size of the family influence the risk of inflammatory bowel disease:A Slovak case-control study显示文摘 | Hlavaty T Toth J Koller T | 2013 | United European Gastroenterology Journal2013，1，2： | 1 |
| 7 | 肠肌层神经丛炎预测克罗恩病术后早期复发的价值 | Ferrante M. de Hertogh G. Hlavaty T. G.van Assche 尹勇 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，0，10： | 1 |
| 8 | Mass spectroscopy as a discovery tool for identifying serum markers for prostate cancer 显示文摘 | Hlavaty JJ Partin AW Kusinitz F | 2001 | Clin Chem2001，47，： | 1 |
| 9 | Intramural esophageal dis- section 显示文摘 | Lucenic M Zsemlye Z Hlavaty T | 2013 | Rozhl Chit2013，92，8： | 1 |
| 10 | Prevalence of liver disease markers among patients with metabolic risk factors 显示文摘 | Koller T Kollerovd J Hlavaty T | 2010 | Vnitr Lek2010，56，3： | 1 |
| 11 | Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors显示文摘 | Koller T Kollerova J Hlavaty T | 2012 | Scand J Gastroenterol2012，47，2： | 1 |
| 12 | Suicide genes for cancer therapy 显示文摘 | Portsmouth D Hlavaty J Renner M | 2007 | Mol Aspects Med2007，28，1： | 1 |
| 13 | Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors 显示文摘 | Juraj Hlavaty Matthias Schittmayer | 2005 | Virology2005，341，： | 1 |
| 14 | The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women 显示文摘 | Kunesova M Braunerova R Hlavaty P | 2006 | Physiol Res2006，55，1： | 1 |
| 15 | Suicide genes for cancer therapy 显示文摘 | Portsmouth D Hlavaty J Rennet M | 2007 | Mol Aspects Med2007，28，1： | 1 |
| 16 | Electrochemical polymerization of N-alkenylpyrroles显示文摘 | Hlavaty J Papez V Kavan L | 1994 | Synthetic Metals1994，66，2： | 1 |
| 17 | Organic elcctrosynthesis on a laboratory scale 显示文摘 | Manousek O Volke J Hlavaty J | 1980 | Electrochim Acta1980，25，5： | 1 |
| 18 | Suicide genes for cancer therapy显示文摘 | PORTSMOUTH D HLAVATY J RENNER M | 2007 | Mol Aspects Med2007，28，1： | 1 |
| 19 | Variation in the vitamin D receptor gene is not associated with risk of colorectal cancer in the Czech Republic 显示文摘 | Hughes DJ Hlavati I Soucek P | 2011 | Gastrointest Cancer2011，42，3： | 1 |
| 20 | 显示文摘 | Hlavaty P Kunesova M | 2006 | Cas Lek Cesk2006，145，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员